ASRT Assertio Holdings, Inc.

BULLISH Impact: 8/10 8-K
Horizon weeks Filed May 18, 2026 Processed 25d 22h ago SEC 0001104659-26-063064
8-K context-dependent: Items 8.01
Latest settled — T+5d
ASRT ▲ +0.60% at T+5d
LONG call ✓ call won +0.60% · α vs SPY -1.02% · entry $23.32 → $23.46
Next anchor: T+20d in 3d
Currently $23.48 · +0.69% from $23.32 entry
Entry anchored
May 15, 03:59 PM ET
via Databento tick
T+1d
+0.39%
call +0.39% · α +1.04%
$23.41
settled 25d ago
T+5d
+0.60%
call +0.60% · α -1.02%
$23.46
settled 18d ago
T+20d
call — · α —
in 3d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Assertio Holdings announced it has entered into a definitive merger agreement with Zydus Worldwide DMCC, under which Zydus will acquire all outstanding shares of Assertio common stock for $23.50 per share in cash via a tender offer. The offer price represents a substantial premium to the current market cap of ~$151M, and the transaction is expected to close subject to customary conditions. This is a transformative event that will take the company private.

Actionable Insight

Traders should expect ASRT shares to trade up toward the $23.50 offer price as arbitrageurs price in deal completion. Monitor for any competing bids, regulatory hurdles, or shareholder lawsuits that could delay or derail the transaction. The waiver of the note offer removes a potential overhang on the convertible notes.

Key Facts

  • Merger agreement with Zydus Worldwide DMCC at $23.50 per share in cash
  • Cash tender offer for all outstanding common stock commenced May 18, 2026
  • Offer price implies a significant premium to the $151M market cap
  • Parent waived requirement for concurrent note offer on the 6.50% Convertible Senior Notes due 2027
  • Merger will constitute a Fundamental Change under the indenture, triggering noteholder rights

Financial Impact

Acquisition at $23.50 per share in cash; total deal value not disclosed but based on market cap of $151M, the premium is substantial

share pricedilutiondebt

Risk Factors

  • Transaction may not close due to regulatory or antitrust issues
  • Shareholders may not tender sufficient shares
  • Competing bids could emerge but are unlikely given the definitive agreement
  • Litigation challenging the deal could delay closing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
60% bullish (10 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-063064
Document: 0001104659-26-063064-index-headers.html0001104659-26-063064
Document: 0001104659-26-063064-index.html0001104659-26-063064
Document: 0001104659-26-063064.txt0001104659-26-063064
6 reports for ASRT
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for ASRT — sortable, filterable
Type Now
May 18, 2026
25d ago
8-K
BULLISH ★ 8/10
$23.32 $23.46▲ +0.60%▼ −1.02%$23.48 (+0.69%)
May 8, 2026
5w ago
8-K
NEUTRAL ★ 3/10
$22.50 $23.32▲ +3.64%▲ +2.18%$23.48 (+4.36%)
May 5, 2026
5w ago
8-K
NEUTRAL ★ 3/10
$22.16 $22.36▲ +0.90%▼ −1.08%$23.48 (+5.96%)
May 4, 2026
5w ago
8-K
BULLISH ★ 8/10
$21.61 $22.36▲ +3.47%▲ +0.53%$23.48 (+8.65%)
Apr 29, 2026
6w ago
8-K
NEUTRAL ★ 3/10
$18.43 $22.37▲ +21.38%▲ +19.65%$23.48 (+27.40%)
Apr 9, 2026
9w ago
8-K
BULLISH ★ 8/10
$18.02 $18.02· 0.00%▼ −3.19%$23.48 (+30.30%)
Showing 6 of 6

US Market Status

Market Closed — Opens Mon (49h 40m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access